We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks.
Some of the major U.S. indexes began recovering on Wednesday, following the Trump administration’s announcement of a one-month delay on tariffs for automakers meeting the United States-Mexico-Canada Agreement (USMCA) requirements. The news sparked enthusiasm among traders, who began hoping for additional exemptions, causing the major stock indexes to rise slightly.
Blue-chip companies gained 485.60 points or 1.14%, the broader market index rose 1.12%, while the NASDAQ stocks increased 1.46%. These rebounds come during a volatile week following a period of consecutive declines.
Although many analysts have lowered their U.S. stock forecasts, citing that strong earnings in 2025 may be more challenging to achieve, the broader market index is still projected to end the year about 9% higher than in 2024. However, this is lower than the initial forecast of 12.2%, made in early January.
On the other hand, the big bets for this year are a productivity boost from the adoption of AI and the projection of lower interest rates. Dan Ives, global head of technology research at Wedbush Securities, said that while tariffs are never good for Wall Street, investors should take advantage of these periods to invest in the best tech stocks, reports CNN Business.
Amid market fluctuations and uncertainty, insider trading often attracts significant attention. Executives and insiders, with their in-depth knowledge of company strategies, plans, and future prospects, may make trades worth analyzing. For instance, when a CEO or CFO invests their own funds in company stock, it can serve as a strong indicator of confidence in the company’s future potential.
Selling shares, on the other hand, may suggest that management is losing confidence, though this is not always the case. In some instances, large shareholders may simply be rebalancing their portfolios to better align with their desired risk/reward profile or selling for personal financial reasons. Additionally, many insiders sell shares as part of pre-arranged, automated trading plans known as 10b5-1 plans.
Both insider buying and selling can be influenced by various factors, so these actions should be interpreted within the broader context of the company’s financial health, industry trends, and overall market conditions. This highlights the importance of conducting thorough research before making investment decisions. While insider trading activity can offer valuable insights into a company’s prospects, it should be considered alongside other critical factors to ensure well-informed investment choices.
Today, we’re focusing on stocks that have seen insider sales of at least $10 million since the start of the year. Using Insider Monkey’s insider trading screener, we identified stocks where at least one insider sale reached $10 million or more. While the total value of insider sales for these stocks may be higher, we focused on sales worth $10 million or more. Out of the stocks that met this criterion, we selected the 10 stocks with insider sales ranging from $10 million to $20 million, prioritizing those with the highest insider sales within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million year-to-date, and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $10 million in insider sales since the beginning of the year.
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Highest Individual Sale: $19,507,205.25
Number of Sales Above $10 million: 24
Market Capitalization: $835.05 billion
In the middle of this list of 10 stocks with $10 million in insider sales recently is a multinational pharmaceutical firm, Eli Lilly and Company (NYSE:LLY). Commonly known as Lilly, the Indianapolis, Indiana-headquartered company has offices in 18 countries and its products have reached approximately 125 countries worldwide. It is also one of the top 10 stocks to buy according to Lone Pine Capital.
Lilly is known for its clinical depression drugs Prozac (1986), Cymbalta (2004), and its antipsychotic medication Zyprexa (1996). Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014).
Since the beginning of the year, one insider made 24 sales of Eli Lilly and Company (NYSE:LLY) shares. One of the transactions was worth $19.51 million, during which the insider sold 21,025 shares at a price of $927.81 per share. Currently, the stock is trading at $929.72, having gained 20.43% year-to-date.
Recently, Lilly announced it plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the U.S. This brings the company’s total capital expansion commitments to more than $50 billion since 2020.
Last week, the company also confirmed that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a reversible Bruton’s tyrosine kinase (BTK) inhibitor. The treatment is recommended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have previously been treated with a BTK inhibitor. The news caused its shares to jump 2.713%, from $905.16 to $929.72 per share.
Twenty analysts have an average “Moderate Buy” rating on Eli Lilly and Company (NYSE:LLY) stock, with a price target of $1,007.50 per share, according to MarketBeat.
Overall LLY ranks 5th on our list of the stocks with at least $10 million in insider sales recently. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
